MedTrace Logo

A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis

NCT03133676 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-12-27

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and tolerability of KA34 when administered via intra-articular injection to subjects with osteoarthritis of the knee.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

KA34

50 µg - 400 µg intra-articular injection (single or multiple doses)

DRUG

Placebo

50 µg - 400 µg intra-articular injection (single or multiple doses)

Sponsors & Collaborators

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • Calibr, a division of Scripps Research

    lead OTHER

Principal Investigators

  • Martin Lotz, MD · Calibr, a division of Scripps Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-02
Primary Completion
2020-04-28
Completion
2020-04-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03133676 on ClinicalTrials.gov